Interventional HIV prevention strategy based on pre-exposure prophylaxis (PrEP) with Truvada®
for people in the Île-de-France area (or Paris region) who don't have HIV but who are at high
risk of becoming infected with HIV (men who have sex with men (MSM), transgender men and
women, heterosexual men and women, sex workers, migrants) in combination with overall
prevention services (communautary-based or educational counselling; addiction, social and
psychological care; condoms and lubricating gel; clean injection equipment; sexually
transmitted diseases (STD) screening and treatment; hepatitis A virus (HAV), hepatitis B
virus (HBV) and hepatitis C virus (HCV) vaccinations and post-exposure treatment of HIV
infection as soon as possible after diagnosis using an antiretroviral combination recommended
by the French Guidelines on HIV treatment).
The individual benefit being already demonstrated in clinical trials, the aim is to
demonstrate the public health impact of the interventional HIV prevention strategy by
reducing the risk of getting HIV-1 infection of at least 15% of new diagnosis of HIV
infections among MSM/transgender in the Ile-de-France area after a 3-year period.
Phase:
N/A
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir